Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 31, 2013, Pages 12661-12666

  Völkers, Mirko ^a,b   Toko, Haruhiro ^a,b   Doroudgar, Shirin ^a,b   Din, Shabana ^a,b   Quijada, Pearl ^a,b   Joyo, Anya Y ^a,b   Ornelas, Luis ^a,b   Joyo, Eri ^a,b   Thuerauf, Donna J ^a,b   Konstandin, Mathias H ^a,b   Gude, Natalie ^a,b   Glembotski, Christopher C ^a,b   Sussman, Mark A ^a,b  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROLINE RICH AKT SUBSTRATE OF 40 KDA; PROLINE RICH PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART FUNCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CARDIOMEGALY; MALE; MICE; MULTIPROTEIN COMPLEXES; MUSCLE PROTEINS; MUTATION; MYOCYTES, CARDIAC; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84881097036     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301455110     Document Type: Article

References (36)

1. McMullen JR, et al. (2004) Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109(24): 3050-3055.
2. Buss SJ, et al. (2009) Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 54(25): 2435-2446.
3. Marin TM, et al. (2011) Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 121(3):1026-1043.
4. Paoletti E, Cannella G (2009) Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: The potential role of mammalian target of rapamycin. Transplant Proc 41(6, Suppl):S3-S5.
5. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293.
6. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21-35.
7. Sengupta S, Peterson TR, Sabatini DM (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40(2):310-322.
8. Sancak Y, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25(6):903-915.
9. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9(3):316-323.
10. Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG (2007) PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282(34):24514-24524.
11. Oshiro N, et al. (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282(28): 20329-20339.
12. Wang L, Harris TE, Roth RA, Lawrence JCJ, Jr. (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282(27): 20036-20044.
13. Wiza C, Nascimento EBM, Ouwens DM (2012) Role of PRAS40 in Akt and mTOR signaling in health and disease. AJP: Endocrinology and Metabolism 302(12):E1453-E1460.
14. Kovacina KS, et al. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278(12):10189-10194.
15. Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 101(33):12130-12135.
16. Nascimento EB, et al. (2006) Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes 55(12):3221-3228.
17. Fonseca BD, Lee VH-Y, Proud CG (2008) The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK. Biochem J 411(1):141-149.
18. McMullen JR, et al. (2003) Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100(21):12355-12360.
19. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther 128(1):191-227.
20. Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: A new therapeutic target? Circulation 109(13):1580-1589.
21. Esposito G, et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105(1):85-92.
22. McKinsey TA, Kass DA (2007) Small-molecule therapies for cardiac hypertrophy: Moving beneath the cell surface. Nat Rev Drug Discov 6(8):617-635.
23. Shah AM, Mann DL (2011) In search of new therapeutic targets and strategies for heart failure: Recent advances in basic science. Lancet 378(9792):704-712.
24. Pacak CA, Byrne BJ (2011) AAV vectors for cardiac gene transfer: Experimental tools and clinical opportunities. Mol Ther 19(9):1582-1590.
25. Jaski BE, et al.; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators (2009) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a firstin-human phase 1/2 clinical trial. J Card Fail 15(3):171-181.
26. Kho C, et al. (2011) SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477(7366):601-605.
27. Belke DD, Gloss B, Swanson EA, Dillmann WH (2007) Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and-beta1 improves contractile function in pressure overload-induced cardiachy pertrophy. Endocrinology 148(6):2870-2877.
28. Sakata S, et al. (2007) Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 42(4):852-861.
29. Muraski JA, et al. (2007) Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13(12):1467-1475.
30. Muraski JA, et al. (2008) Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload. Proc Natl Acad Sci USA 105(37):13889-13894.
31. Carraway MS, et al. (2010) Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. Circ Res 106(11):1722-1730.
32. Quijada P, et al. (2012) Preservation of myocardial structure is enhanced by Pim-1 engineering of bone marrow cells. Circulation Research 111(1):77-86.
33. Fischer KM, et al. (2011) Cardiac progenitor cell commitment is inhibited by nuclear Akt expression. Circ Res 108(8):960-970.
34. Völkers M, et al. (2011) The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition. Circ Res 108(1):27-39.
35. Avitabile D, et al. (2011) Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin. Proc Natl Acad Sci USA 108(15):6145-6150.
36. Völkers M, et al. (2012) Orai1 deficiency leads to heart failure and skeletal myopathy in zebrafish. J Cell Sci 125(Pt 2):287-294.